Epstein-Barr virus: Difference between revisions

From IDWiki
(β†’β€: malignancies added)
Line 41: Line 41:
   
 
=== Complications ===
 
=== Complications ===
βˆ’
* Linked to a number of malignancies, including Burkitt lymphoma, nasopharyngeal carcinoma, and lymphoproliferative disorders
+
* Linked to a number of '''malignancies''', including Burkitt lymphoma, nasopharyngeal carcinoma, and lymphoproliferative disorders
 
* Neurologic complications include meningitis, encephalitis, Guillain-BarrΓ© syndromes, optic neuritis, retrobulber neuritis, cranial nerve palsies, mononeuritis multiplex, brachial plexus neuropathy, seizures, subacute sclerosing panencephalitis, transverse, myelitis, psychosis, demyelination, and hemiplegia
 
* Neurologic complications include meningitis, encephalitis, Guillain-BarrΓ© syndromes, optic neuritis, retrobulber neuritis, cranial nerve palsies, mononeuritis multiplex, brachial plexus neuropathy, seizures, subacute sclerosing panencephalitis, transverse, myelitis, psychosis, demyelination, and hemiplegia
  +
  +
=== EBV-associated malignancies ===
  +
{| class="wikitable"
  +
! Disease !! EBV !! Risk factors
  +
|-
  +
| Lymphoproliferative disease || 90% || Transplantation patients and immunosuppression
  +
|-
  +
| Primary CNS lymphoma || 100% || HIV with low CD4 and immunosuppression
  +
|-
  +
| Hodgkin lymphoma || 50% || Children and young adults
  +
|-
  +
| Nasopharyngeal carcinoma || 100% || Southern Chinese, Inuit
  +
|-
  +
| Gastric cancer || 4 to 100% || Unknown
  +
|-
  +
| Burkitt lymphoma || 95% if endemic, 20% sporadic || African children, HIV independent of CD4 count
  +
|}
   
 
== Diagnosis ==
 
== Diagnosis ==

Revision as of 08:59, 24 October 2019

Background

Microbiology

  • A gamma-1 herpesvirus
  • Double-stranded DNA inside an icosahedral protein nucleocapsid surrounded by a lipid envelope with glycoproteins
  • Two strains (type 1 and 2) are serologically identical, but have unique epitopes
  • Infection can remain quiescent in B cells for life

Epidemiology

  • Acquired via oral secretions, e.g. by kissing or sharing of food
  • Seroprevalence about 90-95% in adults, with about half of 5 year-olds already being seropositive
  • Highest morbidity is with young adults who develop infectious mononucleosis during primary disease
    • Includes barracks and universities

Pathophysiology

  • Acquired through mucous membrane contact of oral secretions
  • Immune response primarily with cytotoxic T cells and NK cells
    • Atypical lymphocytosis develops from CD8 cells
  • Early response is against lytic antigens (including VCA and EA), and later response against latent proteins (EBNA1, EBNA2, EBNA3, and EBNALP)
  • Response also creates IgM antibodies to sheep, horse, and cow RBCs, called heterophile antibodies

Clinical Presentation

Childhood

  • In childhood, mostly asymptomatic or mild febrile illness
  • May develop rashes, neutropenia, or pneumonia
  • Can cause lymphadenopathy
  • Heterophile antibody may be negative if young; about 80% are positive by 4 years, though

Infectious mononucleosis

  • Caused by primary infection, typically in an adolescent or young adult
  • Incubation period 30 to 50 days, and can have asymptomatic viral shedding for up to a month before symptoms
  • Causes about 80% of mononucleosis, with the rest being CMV
  • Symptoms include a triad of sore throat, fever, and lymphadenopathy
    • Often preceded by prodromal symptoms of chils, sweats, anorexia, and malaise
    • Can also have retro-orbital headaches, myalgias, and abdominal discomfort
    • May have a rash which can take any form, and may have palatal petechiae
    • Tonsils are sometimes exudative
    • Often has splenomegaly, may have hepatomegaly, and rarely has jaundice
  • With exposure to amoxicillin, almost all patients develop a diffuse maculopapular rash
  • May have transient heterophile antibodies, as well as atypical lymphocytosis
  • Resolves over 2 to 3 weeks, with fevers lasting up to 14 days

Complications

  • Linked to a number of malignancies, including Burkitt lymphoma, nasopharyngeal carcinoma, and lymphoproliferative disorders
  • Neurologic complications include meningitis, encephalitis, Guillain-BarrΓ© syndromes, optic neuritis, retrobulber neuritis, cranial nerve palsies, mononeuritis multiplex, brachial plexus neuropathy, seizures, subacute sclerosing panencephalitis, transverse, myelitis, psychosis, demyelination, and hemiplegia

EBV-associated malignancies

Disease EBV Risk factors
Lymphoproliferative disease 90% Transplantation patients and immunosuppression
Primary CNS lymphoma 100% HIV with low CD4 and immunosuppression
Hodgkin lymphoma 50% Children and young adults
Nasopharyngeal carcinoma 100% Southern Chinese, Inuit
Gastric cancer 4 to 100% Unknown
Burkitt lymphoma 95% if endemic, 20% sporadic African children, HIV independent of CD4 count

Diagnosis

Serology

  • Anti-VCA (viral capsid antigens): most useful
    • Anti-VCA IgM: appears early and disappears within 4 to 6 weeks
    • Anti-VCA IgG: appears in acute phase, peaks at 2 to 4 weeks, then declines but remains positive for life
  • Anti-EA (early antigen) IgG: appears in acute phase and falls to undetectable within 3 to 6 months (but may persist for years)
    • Least useful test
  • Anti-EBNA (EBV nuclear antigen): negative during acute phase converts after 2 to 4 months and stays positive for life
  • Monospot test: cross-reacts with many other conditions, and is often falsely negative in children

Immunocompetent hosts

VCa-IgM VCA-IgG EBNA-IgG Interpretation
– – – Susceptible
– – + Past infection or non-specific
– + – Acute or past infection
– + + Past infection
+ – – Acute infection or non-specific
+ – + Uninterpretable
+ + – Acute infection
+ + + Late primary infection or reactivation

EBV-associated diseases

Disease VCA-IgM VCA-IgG VCA-IgA EA(D)-IgG EA(R)-IgG EA-IgA EBNA-IgG
Chronic active infection Β± ++ Β± + ++ – Β±
Burkitt lymphoma – ++ – Β± ++ – +
ENT carcinoma – ++ + ++ Β± + +
Hodgkin lymphoma – ++ – + – – +
Reactivation Β± ++ Β± + Β± Β± Β±

References

  1. ^  Massimo De Paschale. Serological diagnosis of Epstein-Barr virus infection: Problems and solutions. World Journal of Virology. 2012;1(1):31. doi:10.5501/wjv.v1.i1.31.